1st Quarter - Amendment

ASSOCIATION FOR ACCESSIBLE MEDICINES for ASSOCIATION FOR ACCESSIBLE MEDICINES

Firm
Client
Income
—
Expenses
$720,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report Apr 20, 2017 $720,000 Replaced
1st Quarter - Amendment (this page) Jul 20, 2017 $720,000 Yes

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Trans-Pacific Partnership (TPP). Transatlantic Trade and Investment Partnership (TTIP). Biologic Exclusivity. USTR Confirmation.

LobbyistCovered position, as disclosed
CHRISTOPHER BOWLIN —
MICHAEL BRZICA —
KATHRYN LEE ANDERSON CHADWICK —
CHRISTIAN OMAR CRUZ —
JEFFREY FRANCER New —
ERIK C KOMENDANT New Legislative Director, Rep. Jason Altmire; Legislative Correspondent/Legislative Assistant, Rep. Zoe Lofgren
HEIDI WILSON —

Contacted: SENATE; Food & Drug Administration (FDA); White House Office; HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

Taxation Issues Related to Opioid Pharmaceuticals. User Fee Programs.

LobbyistCovered position, as disclosed
CHRISTOPHER BOWLIN —
MICHAEL BRZICA —
KATHRYN LEE ANDERSON CHADWICK —
CHRISTIAN OMAR CRUZ —
CHESTER DAVIS —
JEFFREY FRANCER New —
DAVID R. GAUGH New —
ERIK C KOMENDANT New Legislative Director, Rep. Jason Altmire; Legislative Correspondent/Legislative Assistant, Rep. Zoe Lofgren
HEIDI WILSON —

Contacted: Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES; White House Office

Copyright/Patent/Trademark CPT

Inter Partes Review (IPR) process. Patent Settlements.

LobbyistCovered position, as disclosed
CHRISTOPHER BOWLIN —
MICHAEL BRZICA —
KATHRYN LEE ANDERSON CHADWICK —
CHRISTIAN OMAR CRUZ —
THOMAS JAMES GARRIGAN —
ERIK C KOMENDANT New Legislative Director, Rep. Jason Altmire; Legislative Correspondent/Legislative Assistant, Rep. Zoe Lofgren
HEIDI WILSON —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; White House Office; Food & Drug Administration (FDA)

Medicare/Medicaid MMM

Medicare Part D Program and Generic Drugs. Medicare reimbursement for biosimilars. Medicaid Rebate Penalty. Medicare Part D Low Income Subsidy (LIS) Program.

LobbyistCovered position, as disclosed
CHRISTOPHER BOWLIN —
MICHAEL BRZICA —
KATHRYN LEE ANDERSON CHADWICK —
CHRISTIAN OMAR CRUZ —
CHESTER DAVIS —
THOMAS JAMES GARRIGAN —
ERIK C KOMENDANT New Legislative Director, Rep. Jason Altmire; Legislative Correspondent/Legislative Assistant, Rep. Zoe Lofgren
CHRISTINE SIMMON —
HEIDI WILSON —

Contacted: White House Office; Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES

Budget/Appropriations BUD

FDA Funding. S.2956: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017. H.R.5054: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017. S.Con.Res.3: A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.

LobbyistCovered position, as disclosed
CHRISTOPHER BOWLIN —
MICHAEL BRZICA —
KATHRYN LEE ANDERSON CHADWICK —
CHRISTIAN OMAR CRUZ —
JEFFREY FRANCER New —
DAVID R. GAUGH New —
ERIK C KOMENDANT New Legislative Director, Rep. Jason Altmire; Legislative Correspondent/Legislative Assistant, Rep. Zoe Lofgren
HEIDI WILSON —

Contacted: SENATE; White House Office; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Bills named: S. 2956 (115th), H.R. 5054 (115th), S.Con.Res. 3 (115th)

Pharmacy PHA

Implementation of Food and Drug Administration Safety and Innovation Act (FDASIA) and Generic Drug User Fee Amendments (GDUFA). Biosimilar User Fee Act (BsUFA). Labeling of Generic Drugs. Biosimilars Naming. Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products. Prescription Drug Costs. H.R.2841: FAST Generics Act of 2015. H.R.1314: Bipartisan Budget Act of 2015. Risk Evaluation and Mitigation Strategies (REMS). Biologic Exclusivity. Biologics Price Competition and Innovation Act (BPCIA). Pharmaceutical Exclusivity. S.3056: CREATES Act of 2016. H.R.6043/S.3335: Fair Accountability and Innovative Research Drug Pricing Act of 2016. S.297: Increasing Competition in Pharmaceuticals Act. H.R.749: Lower Drug Costs through Competition Act. Drug Importation.

LobbyistCovered position, as disclosed
CHRISTOPHER BOWLIN —
MICHAEL BRZICA —
KATHRYN LEE ANDERSON CHADWICK —
CHRISTIAN OMAR CRUZ —
CHESTER DAVIS —
JEFFREY FRANCER New —
THOMAS JAMES GARRIGAN —
DAVID R. GAUGH New —
ERIK C KOMENDANT New Legislative Director, Rep. Jason Altmire; Legislative Correspondent/Legislative Assistant, Rep. Zoe Lofgren
CHRISTINE SIMMON —
HEIDI WILSON —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE; White House Office

Bills named: H.R. 2841 (115th), H.R. 6043 (115th), H.R. 749 (115th), S. 297 (115th), S. 3335 (115th), S. 3056 (115th), H.R. 1314 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.